Target institutions Focus on expanding partnerships with leading research universities, medical centers, and national laboratories already listed as customers or potential users of immunoassay reagents, leveraging their demand for validated monoclonal and polyclonal antibodies, antigens, and cardiac markers.

In vitro shift Highlight the new in vitro produced antibodies as a selling point to customers seeking alternatives to traditional in vivo production, offering potential for scalable supply and compliance with specific regulatory or ethical preferences.

Diagnostics demand Leverage strengths in infectious disease, cardiovascular biomarkers, hormones, and influenza reagents to target diagnostic assay developers and clinical laboratories needing validated reagents for quantitative and qualitative testing.

Certified capability Emphasize ISO 9001 certification and WBENC woman-owned status to appeal to procurement teams with supplier diversity goals and quality management requirements, potentially unlocking new contracts and preference programs.

Global reach Promote worldwide availability of reagents for diverse disciplines and rapid testing needs to international biotechnology firms and contract research organizations seeking reliable, validated immunological reagents and fast lead times.